Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

Rosak, C.; Mertes, Gabriele

doi:10.2147/dmso.s28340

Cited by 186 publications

(135 citation statements)

References 88 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…The main reason for this is that fermentation of undigested carbohydrates by bacteria produced gas in the colon. 3) Acarbose and voglibose treatment delayed starch digestion in the small intestine but there was compensatory salvage through bacterial fermentation in the large intestine. 4) When carbohydrates (starch, dietary fiber) enter the large intestine, they are degraded by the fermentation of anaerobic flora.…”

mentioning

confidence: 98%

Comparisons of Effects on Intestinal Short-Chain Fatty Acid Concentration after Exposure of Two Glycosidase Inhibitors in Mice

Cai

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Acarbose and voglibose are the most widely used diabetes drugs as glycosidase inhibitors. In this study, the use of these two inhibitors significantly increased the content of starch in large intestine, and altered the concentration of short-chain fatty acids (SCFAs) by affecting the intestinal microbiota. However, there are some differences in the intestinal microbiome of the two groups of mice, mainly in bacteria such as Bacteroidaceae bacteroides and Desulfovibrionaceae desulfovibrio. The productions of acetate and propionate in caecum in voglibose group were significantly higher than those in acarbose group and two kinds of glycosidase inhibitors were close in the production of butyrate in caecum. The Tax4Fun analysis based on Kyoto Encyclopedia of Genes and Genomes (KEGG) data indicated that different productions of acetate and propionate between acarbose group and voglibose group may be related to 2-oxoisovalerate dehydrogenase and pyruvate oxidase. In addition, in-vitro experiments suggested that voglibose had less effect on epithelial cells than acarbose after direct stimulation. According to the recent researches of SCFAs produced by intestinal microbiota, our comparative study shown higher concentration of these beneficial fatty acids in the lumen of voglibose-treated mice, which implied a lower level of inflammation.Key words acarbose; voglibose; microbiota; short-chain fatty acid; Tax4FunWith the increasing number of obesity and diabetes around the world, there are more and more different classes of medications to treat diabetes, such as biguanides (metformin), sulfonylureas, insulin, glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase IV inhibitors, thiazolidinediones and sodium-glucose transporter 2 inhibitors (to name a few). 1) However, acarbose and voglibose as part of α-glucosidase inhibitors (AGIs) are another class of anti-diabetic medications. As first-line hypoglycemic drugs used in patients with type 2 diabetes especially in Asian since their diet meals contain high content of carbohydrates, acarbose and voglibose can typically reduce postprandial glucose level by delaying carbohydrate digestion in the gut, so they can be a useful treatment in the patients who raised basal glucose concentrations slightly and marked postprandial hyperglycemia. 2) In addition, there will also be some side effects, mainly reflected in gastrointestinal flatulence, loose stool and so on. The main reason for this is that fermentation of undigested carbohydrates by bacteria produced gas in the colon. 3) Acarbose and voglibose treatment delayed starch digestion in the small intestine but there was compensatory salvage through bacterial fermentation in the large intestine. 4) When carbohydrates (starch, dietary fiber) enter the large intestine, they are degraded by the fermentation of anaerobic flora. 5) Under normal diet situations, the better part of starch was digested and absorbed in the small intestine, therefore, extra starch entering the large bowel changed microbial eco-system to some degree. Som...

show abstract

mentioning

confidence: 98%

Comparisons of Effects on Intestinal Short-Chain Fatty Acid Concentration after Exposure of Two Glycosidase Inhibitors in Mice

Cai

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…The risk of hypoglycemia with DPP-4 inhibitors is low (26–28). Most of the DPP-4 inhibitors are excreted by the kidneys except for linagliptin; therefore, dose restrictions may be advisable for some patients.AGIs have modest AlC-lowering effects and low risk for hypoglycemia (29). Clinical trials have shown CVD benefit in patients with impaired glucose tolerance and diabetes (14,30).…”

Section: Executive Summarymentioning

confidence: 99%

“…AGIs have modest AlC-lowering effects and low risk for hypoglycemia (29). Clinical trials have shown CVD benefit in patients with impaired glucose tolerance and diabetes (14,30).…”

Section: Executive Summarymentioning

confidence: 99%

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

Garber¹,

Abrahamson²,

Barzilay³

et al. 2013

Endocrine Practice

222

190

View full text Add to dashboard Cite

“…This drug inhibits the upper gastrointestinal glucosidases enzymes that convert complex polysaccharide carbohydrates into monosaccharides in a dose-dependent fashion, resulting in a delayed glucose absorption and a lowering of postprandial hyperglycemia. However, gastrointestinal side effects, including mainly flatulence and sometimes soft stools or abdominal discomfort, have been reported as a limiting factor for patients treatment [41,42].…”

Section: α-Glucosidase Inhibitionmentioning

confidence: 99%

Nanoencapsulation of dietary flavonoid fisetin: Formulation and in vitro antioxidant and α-glucosidase inhibition activities

Sechi

Syed

Pala

et al. 2016

Materials Science and Engineering: C

View full text Add to dashboard Cite

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

Cited by 186 publications

References 88 publications

Comparisons of Effects on Intestinal Short-Chain Fatty Acid Concentration after Exposure of Two Glycosidase Inhibitors in Mice

Comparisons of Effects on Intestinal Short-Chain Fatty Acid Concentration after Exposure of Two Glycosidase Inhibitors in Mice

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

Nanoencapsulation of dietary flavonoid fisetin: Formulation and in vitro antioxidant and α-glucosidase inhibition activities

Contact Info

Product

Resources

About